Astrazeneca Brings CRESTOR® To India

Makes a highly effective treatment for an estimated 45 million patients of coronary artery disease affordable for patients in India

Gurgaon, Haryana, April 15, 2009 /India PRwire/ -- AstraZeneca India announced the launch of CRESTOR® (rosuvastatin) 5, 10, 20 and 40 mg tablets today. CRESTOR® is indicated for use in the treatment of dyslipidemia, atherosclerosis and primary hypercholesterolaemia. Dyslipidemia is a clinical condition characterized by an elevation of cholesterol and/or triglycerides in the bloodstream. Over 69% of patients with coronary heart disease, even those currently on medications, remain above the targeted levels for cholesterol.

Atherosclerosis is the term used to describe the process when plaque, composed of cholesterol, fatty substances, builds up on the inside walls of the arteries. As plaque builds, it hardens and narrows the arteries, which can eventually lead to cardiovascular disease – often causing chest pain (angina) heart attack, heart failure and stroke.

CRESTOR® (rosuvastatin) is a new member of the cholesterol-lowering statin (HMG-CoA reductase inhibitors) class of drug therapy. In addition to its LDL (low-density lipoprotein) or “bad” cholesterol lowering effects, CRESTOR®, has been shown to provide a significant increase in HDL (high-density lipoprotein) or “good” cholesterol. For the first time a statin could slow down and reverse the progression of atherosclerosis, the leading cause of heart attack and stroke.

“We are delighted to introduce CRESTOR®, the original rosuvastatin in India,“ said Anandh Balasundaram, Managing Director, AstraZeneca Pharma India Ltd. “We believe that CRESTOR® offers an important treatment option for the large patient pool who are either untreated or not at target cholesterol levels. The launch of CRESTOR® is in line with our India strategy to bring global brands to India at prices affordable for Indian patients.”

The clinical development program for CRESTOR® is the largest program ever submitted to evaluate a statin initially. In multiple clinical studies, CRESTOR® has been shown to be more effective in lowering LDL-cholesterol than currently prescribed statins, these studies have been published in leading international medical journals. Evidence collected from over 30,000 patients who have taken CRESTOR® demonstrates that it is well tolerated with a safety profile comparable to that of other statins.

This introduction is especially significant as current projections suggest that by the year 2020 India will have the largest cardiovascular disease burden in the world and account for one third of all deaths, with one fifth of the deaths in India resulting from coronary heart disease. Sadly, many of these deaths will be among young Indians, also because heart disease in India occurs 8 to 10 years earlier than in the West. Even women are prone to the risk as one in four women in urban India and every eighth woman in rural India is suffering from high cholesterol.

Notes to Editor

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US$ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. For more information about AstraZeneca, please visit: www.astrazeneca.com

About AstraZeneca India

In India, with over 1500 employees, AstraZeneca’s presence includes:

AstraZeneca Pharma India Limited (AZPIL), the Operating Company, with products in seven major therapeutic areas - Oncology, Cardiovascular, Maternal Healthcare, Gastrointerstinal, Infection, Respiratory & Neuroscience and a world-class manufacturing unit conforming to WHO current Good Manufacturing Practices (cGMP).

AstraZeneca India Pvt. Ltd. (AZIPL), the centre of excellence established in 1996, and an integrated part of the AstraZeneca R&D network, is the only MNC in India focused on discovering novel drugs or therapies for tuberculosis. In addition, a recently constructed state-of-the-art Process R&D facility, built adjacent to the R&D facility, commenced operations to help AstraZeneca maximize the scientific interactions and enable shared use of the R&D infrastructure.

Journalists and Bloggers
Visit India PRwire for Journalists for releases, photos, email alerts and customized feeds just for Media.

If you have any query regarding information in the press releases, please contact the company listed in the press release itself. Please do not call India PRwire, we will be unable to assist you with your inquiry.


R&PM Edelman recent press release(s)


Manage your weight with 'THE PISTACHIO PRINCIPLE'

"The Pistachio Principle," has been developed by behavioral eating expert Dr. James Painter, professor and chair of School of Family and Consumer Sciences at Eastern Illinois University. For sixteen years, Painter has studied how, why and what Americans eat.

Wonderful Pistachios - Anytime healthy munch

Wonderful® Pistachios offers packs in convenient sizes

Sanofi-aventis launches 'I Am A Champ' program to celebrate diabetes control

Malka Verma from Delhi amongst 7 National diabetes champions announced at a first-of-its-kind national awards ceremony in Mumbai

TUBORG STRONG wins 2 prestigious accolades within 6 months of its launch

Within the first six months of its launch in India, Tuborg Strong was awarded the Connoisseur's Choice Award and the New Product of the Year Award at INDSPIRIT 2010, a noted award event for the Alcobev industry. Selected by an eminent jury and certified by ERNST & YOUNG, the award is a resounding victory for this new beer brand.

Pistachios Make Other Nuts "Green" With Envy

Five New Studies Show a Handful or Two of Pistachios are Heart-Healthy, Antioxidant-Packed, Good for Eyesight and More